Skip to main
JNCE
JNCE logo

Jounce Therapeutics (JNCE)

$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy Jounce Therapeutics (JNCE) Stock

About Jounce Therapeutics (JNCE)

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
Market cap$98.95M
Today's volume
Revenue (TTM)
Avg. daily volume3.02M
EBITDA (TTM)
Open
Price / earnings ratio-1.91x
Today's range
Debt / equity
52 week range$0.58 - $5.87
5 year debt / equity4.76x
Beta (LTM)0.52x
Interest coverage
Dividend & yield$0.00 (0.00%)
Current ratio
Ex-dividend date
Next earningsMar 10, 2023
Dividend payable date

Frequently Asked Questions (FAQ)

As of Aug 01, 2025, the market cap for JNCE stock is $98.96M

The current P/E ratio for JNCE stock is -1.91

The 52-week high for JNCE stock is $5.87. The current JNCE stock price $undefined is 100.00% below its 52-week high

The 52-week low for JNCE stock is $0.58. The current JNCE stock price $undefined has increased 100.00% from its 52-week low

No, the JNCE stock does not pay dividends to its shareholders

How to buy JNCE stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in JNCE stock

    Navigate to the Explore page. Then, type JNCE into the search bar. When you see JNCE stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased JNCE stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Jounce Therapeutics Stock Earnings

The value each JNCE share was expected to gain vs. the value that each JNCE share actually gained.

Jounce Therapeutics (JNCE) reported Q4 2022 earnings per share (EPS) of $0.98, beating estimates of -$0.19 by 615.79%. In the same quarter last year, Jounce Therapeutics's earnings per share (EPS) was -$0.59. Jounce Therapeutics is expected to release next earnings on 03/10/2023, with an earnings per share (EPS) estimate of $0.

Buy Jounce Therapeutics (JNCE) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.